Products for Research Use Only

Ninerafaxstat

CAT: 0804-HY-139577-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-139577-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Ninerafaxstat (IMB-1018972) is a novel orally active cardiac mitochondrial drug that restores myocardial energy homeostasis. Ninerafaxstat competitively inhibits 3-ketoacyl-CoA thiolase (3-KAT) to partially suppress fatty acid oxidation, and shifts cardiac energy metabolism from free fatty acid oxidation to glucose oxidation, regulating myocardial substrate utilization and thereby improving cardiac efficiency. Ninerafaxstat can be used for research on cardiovascular diseases[1][2].
CAS Number
2254741-41-6
Product Name Alternative
IMB-1018972; IMB-101
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Mitochondrial Metabolism
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Metabolic Disease; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/ninerafaxstat.html
Purity
99.14
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(C1=CC=CN=C1)OCCN2CCN(CC2)CC3=CC=C(C(OC)=C3OC)OC
Molecular Formula
C22H29N3O5
Molecular Weight
415.48
Precautions
H302, H315, H319, H335
References & Citations
[1]Moritz Hundertmark MD, et al. Kiosk 11R-TC-08 - Ninerafaxstat Modulates Cardiac Energy Metabolism in Cardio-metabolic Syndromes: A Mechanistic, Hyperpolarized MR Trial. Journal of Cardiovascular Magnetic Resonance. 2024; 26: 100325.|[2]Paul Chamberlin, et al. IMB-1018792, A NOVEL FIRST-IN CLASS PARTIAL FATTY ACID OXIDATION INHIBITOR IMPROVES CARDIAC REMODELING AND FUNCTION POST-MYOCARDIAL INFARCTION. J Am Coll Cardiol. 2021 May 11;77 (18) :539.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2